Do you routinely perform next-generation sequencing on otherwise "low-risk" GIST to guide adjuvant therapy?
Given that risk definitions are based on size, mitotic activity, location and not necessarily genetics/biology, would an otherwise low-risk GIST, who would not currently receive adjuvant therapy, benefit from tumor sequencing to guide adjuvant therapy?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
Yes and no. Defining the molecular make up of a newly diagnosed GIST is recommended and helpful in defining therapy. But the mutational status generally does not dictate adjuvant therapy. That decision is based on clinico-pathologic factors and if "low-risk" based on those criteria, close observatio...
Join for free or sign in to see the full answer